Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Inactivation of chronic wasting disease prions using sodium hypochlorite.

Williams K, Hughson AG, Chesebro B, Race B.

PLoS One. 2019 Oct 4;14(10):e0223659. doi: 10.1371/journal.pone.0223659. eCollection 2019.

2.

Microglia are not required for prion-induced retinal photoreceptor degeneration.

Striebel JF, Race B, Williams K, Carroll JA, Klingeborn M, Chesebro B.

Acta Neuropathol Commun. 2019 Mar 25;7(1):48. doi: 10.1186/s40478-019-0702-x.

3.

Transmission studies of chronic wasting disease to transgenic mice overexpressing human prion protein using the RT-QuIC assay.

Race B, Williams K, Chesebro B.

Vet Res. 2019 Jan 22;50(1):6. doi: 10.1186/s13567-019-0626-2.

4.

Neuroinflammation, Microglia, and Cell-Association during Prion Disease.

Carroll JA, Chesebro B.

Viruses. 2019 Jan 15;11(1). pii: E65. doi: 10.3390/v11010065. Review.

5.

Toll-like receptor 2 confers partial neuroprotection during prion disease.

Carroll JA, Race B, Williams K, Chesebro B.

PLoS One. 2018 Dec 31;13(12):e0208559. doi: 10.1371/journal.pone.0208559. eCollection 2018.

6.

Microglia Are Critical in Host Defense against Prion Disease.

Carroll JA, Race B, Williams K, Striebel J, Chesebro B.

J Virol. 2018 Jul 17;92(15). pii: e00549-18. doi: 10.1128/JVI.00549-18. Print 2018 Aug 1.

7.

Lack of Transmission of Chronic Wasting Disease to Cynomolgus Macaques.

Race B, Williams K, Orrú CD, Hughson AG, Lubke L, Chesebro B.

J Virol. 2018 Jun 29;92(14). pii: e00550-18. doi: 10.1128/JVI.00550-18. Print 2018 Jul 15.

8.

Familial human prion diseases associated with prion protein mutations Y226X and G131V are transmissible to transgenic mice expressing human prion protein.

Race B, Williams K, Hughson AG, Jansen C, Parchi P, Rozemuller AJM, Chesebro B.

Acta Neuropathol Commun. 2018 Feb 20;6(1):13. doi: 10.1186/s40478-018-0516-2.

9.

Ultrastructure and pathology of prion protein amyloid accumulation and cellular damage in extraneural tissues of scrapie-infected transgenic mice expressing anchorless prion protein.

Race B, Jeffrey M, McGovern G, Dorward D, Chesebro B.

Prion. 2017 Jul 4;11(4):234-248. doi: 10.1080/19336896.2017.1336274. Epub 2017 Jul 31.

10.

Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Carroll JA, Race B, Phillips K, Striebel JF, Chesebro B.

J Gen Virol. 2017 Aug;98(8):2190-2199. doi: 10.1099/jgv.0.000876. Epub 2017 Jul 31.

11.

Phosphorylated human tau associates with mouse prion protein amyloid in scrapie-infected mice but does not increase progression of clinical disease.

Race B, Phillips K, Kraus A, Chesebro B.

Prion. 2016 Jul 3;10(4):319-30. doi: 10.1080/19336896.2016.1199313.

12.

Prion Strain Differences in Accumulation of PrPSc on Neurons and Glia Are Associated with Similar Expression Profiles of Neuroinflammatory Genes: Comparison of Three Prion Strains.

Carroll JA, Striebel JF, Rangel A, Woods T, Phillips K, Peterson KE, Race B, Chesebro B.

PLoS Pathog. 2016 Apr 5;12(4):e1005551. doi: 10.1371/journal.ppat.1005551. eCollection 2016 Apr.

13.

Knockout of fractalkine receptor Cx3cr1 does not alter disease or microglial activation in prion-infected mice.

Striebel JF, Race B, Carroll JA, Phillips K, Chesebro B.

J Gen Virol. 2016 Jun;97(6):1481-1487. doi: 10.1099/jgv.0.000442. Epub 2016 Mar 2.

14.

Early Generation of New PrPSc on Blood Vessels after Brain Microinjection of Scrapie in Mice.

Chesebro B, Striebel J, Rangel A, Phillips K, Hughson A, Caughey B, Race B.

MBio. 2015 Sep 22;6(5):e01419-15. doi: 10.1128/mBio.01419-15.

15.

Increased infectivity of anchorless mouse scrapie prions in transgenic mice overexpressing human prion protein.

Race B, Phillips K, Meade-White K, Striebel J, Chesebro B.

J Virol. 2015 Jun;89(11):6022-32. doi: 10.1128/JVI.00362-15. Epub 2015 Mar 25.

16.

Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction.

Carroll JA, Striebel JF, Race B, Phillips K, Chesebro B.

J Virol. 2015 Feb;89(4):2388-404. doi: 10.1128/JVI.02952-14. Epub 2014 Dec 10.

17.

Proteomics analysis of amyloid and nonamyloid prion disease phenotypes reveals both common and divergent mechanisms of neuropathogenesis.

Moore RA, Sturdevant DE, Chesebro B, Priola SA.

J Proteome Res. 2014 Nov 7;13(11):4620-34. doi: 10.1021/pr500329w. Epub 2014 Aug 29.

18.

Chronic wasting disease agents in nonhuman primates.

Race B, Meade-White KD, Phillips K, Striebel J, Race R, Chesebro B.

Emerg Infect Dis. 2014 May;20(5):833-7. doi: 10.3201/eid2005.130778.

19.

Analysis of two monoclonal antibodies reactive with envelope proteins of murine retroviruses: one pan specific antibody and one specific for Moloney leukemia virus.

Evans LH, Boi S, Malik F, Wehrly K, Peterson KE, Chesebro B.

J Virol Methods. 2014 May;200:47-53. doi: 10.1016/j.jviromet.2014.02.006. Epub 2014 Feb 17.

20.

Distinct patterns of spread of prion infection in brains of mice expressing anchorless or anchored forms of prion protein.

Rangel A, Race B, Phillips K, Striebel J, Kurtz N, Chesebro B.

Acta Neuropathol Commun. 2014 Jan 21;2:8. doi: 10.1186/2051-5960-2-8.

21.

Unusual cerebral vascular prion protein amyloid distribution in scrapie-infected transgenic mice expressing anchorless prion protein.

Rangel A, Race B, Klingeborn M, Striebel J, Chesebro B.

Acta Neuropathol Commun. 2013 Jun 19;1:25. doi: 10.1186/2051-5960-1-25.

22.

Prion protein and susceptibility to kainate-induced seizures: genetic pitfalls in the use of PrP knockout mice.

Striebel JF, Race B, Chesebro B.

Prion. 2013 Jul-Aug;7(4):280-5. doi: 10.4161/pri.25738. Epub 2013 Jul 12. Review.

23.

Lack of influence of prion protein gene expression on kainate-induced seizures in mice: studies using congenic, coisogenic and transgenic strains.

Striebel JF, Race B, Pathmajeyan M, Rangel A, Chesebro B.

Neuroscience. 2013 May 15;238:11-8. doi: 10.1016/j.neuroscience.2013.02.004. Epub 2013 Feb 13.

24.

Non-amyloid and amyloid prion protein deposits in prion-infected mice differ in blockage of interstitial brain fluid.

Rangel A, Race B, Striebel J, Chesebro B.

Neuropathol Appl Neurobiol. 2013 Apr;39(3):217-30. doi: 10.1111/j.1365-2990.2012.01303.x.

25.

Early cytokine elevation, PrPres deposition, and gliosis in mouse scrapie: no effect on disease by deletion of cytokine genes IL-12p40 and IL-12p35.

Tribouillard-Tanvier D, Race B, Striebel JF, Carroll JA, Phillips K, Chesebro B.

J Virol. 2012 Oct;86(19):10377-83. doi: 10.1128/JVI.01340-12. Epub 2012 Jul 11.

26.

Role of cyclophilin A from brains of prion-infected mice in stimulation of cytokine release by microglia and astroglia in vitro.

Tribouillard-Tanvier D, Carroll JA, Moore RA, Striebel JF, Chesebro B.

J Biol Chem. 2012 Feb 10;287(7):4628-39. doi: 10.1074/jbc.M111.269480. Epub 2011 Dec 16.

27.

Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions.

Klingeborn M, Race B, Meade-White KD, Chesebro B.

Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):E1244-53. doi: 10.1073/pnas.1111255108. Epub 2011 Nov 7.

28.

Strain specific resistance to murine scrapie associated with a naturally occurring human prion protein polymorphism at residue 171.

Striebel JF, Race B, Meade-White KD, LaCasse R, Chesebro B.

PLoS Pathog. 2011 Sep;7(9):e1002275. doi: 10.1371/journal.ppat.1002275. Epub 2011 Sep 29.

29.

Increased excitatory amino acid transport into murine prion protein knockout astrocytes cultured in vitro.

Pathmajeyan MS, Patel SA, Carroll JA, Seib T, Striebel JF, Bridges RJ, Chesebro B.

Glia. 2011 Nov;59(11):1684-94. doi: 10.1002/glia.21215. Epub 2011 Jul 15.

30.

In vivo comparison of chronic wasting disease infectivity from deer with variation at prion protein residue 96.

Race B, Meade-White K, Miller MW, Fox KA, Chesebro B.

J Virol. 2011 Sep;85(17):9235-8. doi: 10.1128/JVI.00790-11. Epub 2011 Jun 22.

31.

Crucial role for prion protein membrane anchoring in the neuroinvasion and neural spread of prion infection.

Klingeborn M, Race B, Meade-White KD, Rosenke R, Striebel JF, Chesebro B.

J Virol. 2011 Feb;85(4):1484-94. doi: 10.1128/JVI.02167-10. Epub 2010 Dec 1.

32.

Disinfection and sterilization of prion-contaminated medical instruments.

Belay ED, Schonberger LB, Brown P, Priola SA, Chesebro B, Will RG, Asher DM.

Infect Control Hosp Epidemiol. 2010 Dec;31(12):1304-6; author reply 1306-8. doi: 10.1086/657579. No abstract available.

PMID:
21047181
33.

Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans.

Cohen MJ, Carles M, Brohi K, Calfee CS, Rahn P, Call MS, Chesebro BB, West MA, Pittet JF.

J Trauma. 2010 Jun;68(6):1273-8. doi: 10.1097/TA.0b013e3181db323e.

34.

Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring.

Chesebro B, Race B, Meade-White K, Lacasse R, Race R, Klingeborn M, Striebel J, Dorward D, McGovern G, Jeffrey M.

PLoS Pathog. 2010 Mar 5;6(3):e1000800. doi: 10.1371/journal.ppat.1000800.

35.

Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia.

Cohen MJ, Bir N, Rahn P, Dotson R, Brohi K, Chesebro BB, Mackersie R, Carles M, Wiener-Kronish J, Pittet JF.

J Trauma. 2009 Dec;67(6):1176-81. doi: 10.1097/TA.0b013e3181c1c1bc.

PMID:
20009664
36.

Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.

Roux J, Carles M, Koh H, Goolaerts A, Ganter MT, Chesebro BB, Howard M, Houseman BT, Finkbeiner W, Shokat KM, Paquet AC, Matthay MA, Pittet JF.

J Biol Chem. 2010 Feb 12;285(7):4278-90. doi: 10.1074/jbc.M109.036731. Epub 2009 Dec 8.

37.

Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion.

Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, Carles M, Howard M, Pittet JF.

Crit Care. 2009;13(6):R174. doi: 10.1186/cc8152. Epub 2009 Nov 4.

38.

Susceptibilities of nonhuman primates to chronic wasting disease.

Race B, Meade-White KD, Miller MW, Barbian KD, Rubenstein R, LaFauci G, Cervenakova L, Favara C, Gardner D, Long D, Parnell M, Striebel J, Priola SA, Ward A, Williams ES, Race R, Chesebro B.

Emerg Infect Dis. 2009 Sep;15(9):1366-76. doi: 10.3201/eid1509.090253.

39.

Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels.

Tribouillard-Tanvier D, Striebel JF, Peterson KE, Chesebro B.

J Virol. 2009 Nov;83(21):11244-53. doi: 10.1128/JVI.01413-09. Epub 2009 Aug 26.

40.

Prion infectivity in fat of deer with chronic wasting disease.

Race B, Meade-White K, Race R, Chesebro B.

J Virol. 2009 Sep;83(18):9608-10. doi: 10.1128/JVI.01127-09. Epub 2009 Jul 1.

41.

Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility.

Walter BL, Armitage AE, Graham SC, de Oliveira T, Skinhøj P, Jones EY, Stuart DI, McMichael AJ, Chesebro B, Iversen AK.

AIDS. 2009 Jun 1;23(9):1047-57. doi: 10.1097/QAD.0b013e32832a1806.

42.

Increase in activated protein C mediates acute traumatic coagulopathy in mice.

Chesebro BB, Rahn P, Carles M, Esmon CT, Xu J, Brohi K, Frith D, Pittet JF, Cohen MJ.

Shock. 2009 Dec;32(6):659-65. doi: 10.1097/SHK.0b013e3181a5a632.

43.

Prion protein on astrocytes or in extracellular fluid impedes neurodegeneration induced by truncated prion protein.

Race B, Meade-White K, Race R, Baumann F, Aguzzi A, Chesebro B.

Exp Neurol. 2009 Jun;217(2):347-52. doi: 10.1016/j.expneurol.2009.03.017. Epub 2009 Mar 28.

44.

Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.

Caughey B, Baron GS, Chesebro B, Jeffrey M.

Annu Rev Biochem. 2009;78:177-204. doi: 10.1146/annurev.biochem.78.082907.145410. Review.

45.

Detection of prion infectivity in fat tissues of scrapie-infected mice.

Race B, Meade-White K, Oldstone MB, Race R, Chesebro B.

PLoS Pathog. 2008 Dec;4(12):e1000232. doi: 10.1371/journal.ppat.1000232. Epub 2008 Dec 5.

46.

Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.

Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC.

Science. 2008 Sep 5;321(5894):1343-6. doi: 10.1126/science.1161121.

47.

Neurovirulence of polytropic murine retrovirus is influenced by two separate regions on opposite sides of the envelope protein receptor binding domain.

Peterson KE, Pourciau S, Du M, Lacasse R, Pathmajeyan M, Poulsen D, Agbandje-McKenna M, Wehrly K, Chesebro B.

J Virol. 2008 Sep;82(17):8906-10. doi: 10.1128/JVI.02134-07. Epub 2008 Jun 25.

48.

Role of Erk1/2 activation in prion disease pathogenesis: absence of CCR1 leads to increased Erk1/2 activation and accelerated disease progression.

LaCasse RA, Striebel JF, Favara C, Kercher L, Chesebro B.

J Neuroimmunol. 2008 May 30;196(1-2):16-26. doi: 10.1016/j.jneuroim.2008.02.009. Epub 2008 Apr 8.

49.

Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma?

Ganter MT, Cohen MJ, Brohi K, Chesebro BB, Staudenmayer KL, Rahn P, Christiaans SC, Bir ND, Pittet JF.

Ann Surg. 2008 Feb;247(2):320-6. doi: 10.1097/SLA.0b013e318162d616.

50.

Prion disease induced alterations in gene expression in spleen and brain prior to clinical symptoms.

Kim HO, Snyder GP, Blazey TM, Race RE, Chesebro B, Skinner PJ.

Adv Appl Bioinform Chem. 2008;1:29-50. Epub 2008 Sep 7.

Supplemental Content

Loading ...
Support Center